Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus

被引：40

作者：

Beasley, David W. C. ^{[1
,2
]}

机构：

[1] Univ Texas Med Branch, Dept Microbiol & Immunol, Sealy Ctr Vaccine Dev, Ctr Biodef & Emerging Infect Dis,Inst Human Infec, Galveston, TX 77555 USA

[2] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA

来源：

IMMUNOTHERAPY | 2011年 / 3卷 / 02期

关键词：

monoclonal antibodies; passive immunization; vaccine; West Nile virus; JAPANESE ENCEPHALITIS-VIRUS; HUMANIZED MONOCLONAL-ANTIBODY; CYCLE FLAVIVIRUS VACCINE; ENVELOPE PROTEIN VACCINE; AMINO-ACID SUBSTITUTION; CD8(+) T-CELLS; DNA VACCINE; NEUTRALIZING ANTIBODY; DOMAIN-III; NEW-YORK;

D O I：

10.2217/IMT.10.93

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The emergence of West Nile virus (WNV) in North America in 1999 as a cause of severe neurological disease in humans, horses and birds stimulated development of vaccines for human and veterinary use, as well as polyclonal/monoclonal antibodies and other immunomodulating compounds for use as therapeutics. Although disease incidence in North America has declined since the peak epidemics in 2002-2003, the virus has continued to be annually transmitted in the Americas and to cause periodic epidemics in Europe and the Middle East. Continued transmission of the virus with human and animal disease suggests that vaccines and therapeutics for the prevention and treatment of WNV disease could be of great benefit. This article focuses on progress in development and evaluation of vaccines and immunotherapeutics for the prevention and treatment of WNV disease in humans and animals.

引用

页码：269 / 285

页数：17

共 187 条

[1] Transfusion-transmitted infectious diseases
Allain, Jean-Pierre
Stramer, Susan L.
Carneiro-Proietti, A. B. F.
Martins, M. L.
Lopes da Silva, S. N.
Ribeiro, M.
Proietti, F. A.
Reesink, Henk W.
[J]. BIOLOGICALS, 2009, 37 (02) : 71 - 77
[2] Protective immunity following vaccination
Amanna, Ian J.
Messaoudi, Ilhem
Slifka, Mark K.
[J]. HUMAN VACCINES, 2008, 4 (04): : 316 - 319
[3] [Anonymous], ARCH VIROL S18
[4] West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-associated membrane protein: increased cellular concentration of the transgene product, targeting to the MHC II compartment, and enhanced neutralizing antibody response
Anwar, A
Chandrasekaran, A
Ng, ML
Marques, E
August, JT
[J]. VIROLOGY, 2005, 332 (01) : 66 - 77
[5] ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy
Arroyo, J
Miller, C
Catalan, J
Myers, GA
Ratterree, MS
Trent, DW
Monath, TP
[J]. JOURNAL OF VIROLOGY, 2004, 78 (22) : 12497 - 12507
[6] Bakonyi T, 2006, EMERG INFECT DIS, V12, P618
[7] Novel flavivirus or new lineage of West Nile Virus, central Europe
Bakonyi, T
Hubálek, Z
Rudolf, I
Nowotny, N
[J]. EMERGING INFECTIOUS DISEASES, 2005, 11 (02) : 225 - 231
[8] Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification
Balsitis, Scott J.
Williams, Katherine L.
Lachica, Ruben
Flores, Diana
Kyle, Jennifer L.
Mehlhop, Erin
Johnson, Syd
Diamond, Michael S.
Beatty, P. Robert
Harris, Eva
[J]. PLOS PATHOGENS, 2010, 6 (02)
[9] Genome sequence and attenuating mutations in West Nile virus isolate from Mexico
Beasley, DWC
Davis, CT
Estrada-Franco, J
Navarro-Lopez, R
Campomanes-Cortes, A
Tesh, RB
Weaver, SC
Barrett, ADT
[J]. EMERGING INFECTIOUS DISEASES, 2004, 10 (12) : 2221 - 2224
[10] Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein
Beasley, DWC
Barrett, ADT
[J]. JOURNAL OF VIROLOGY, 2002, 76 (24) : 13097 - 13100

← 1 2 3 4 5 6 7 8 9 10 →